Fagron NV

Chart & Performance

D1W1MN

P/E

18.83

P/S

1.74

EPS

1.10

Div Yield, %

1.45%

Shrs. gr., 5y

-0.02%

Rev. gr., 5y

10.28%

Revenues

872m

+14.28%

Net income

81m

+14.18%

CFO

110m

+2.34%

Dividend

May 21, 20240.3 EUR/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines. Further, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. It has operations in Latin America, North America, Europe, the Middle East, and Africa. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

URL

https://fagron.com/

IPO date

Oct 05, 2007

Employees

3,035

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT